Quantitative Transmission Imaging Evaluation (QTIE Study) Compared With MRI as Supplemental Screening in Patients With High Lifetime Risk of Breast Cancer
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.
• Women 18+ years of age
• High lifetime risk of breast cancer as determined by a risk assessment tool such a Tyrer-Cuzick model
• Clinical ordered screening MRI.
⁃ MRI and QTI performed within 30 days of each other
• Breasts that will fit in the quantitate transmission (QT) Ultrasound Breast Scanner (e.g. bra cup size less than DDD)